Evolent Health, Inc. Receives $49.22 Consensus Target Price from Analysts
October 11, 2022
Trending News 🌥️
Evolent Health ($NYSE:EVH), Inc. has received an average rating of “Buy” from the fifteen analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and nine have given a buy rating to the company.
Stock Price
The company’s stock opened at $34.90 on Monday and closed at $34.50, down 1.5% from its last closing price of $35.00. Media sentiment towards the company is mostly neutral.
VI Analysis
A company’s fundamentals are its long-term potential indicators. The VI app analyzes a company’s financial and business aspects to provide a risk rating. EVOLENT HEALTH is a high risk investment based on the VI Risk Rating. The app highlights potential risks in the company’s financial and business areas.
Summary
Investing in Evolent Health could be a smart move, as analysts have set a consensus target price of $49.22 for the company. Right now, media sentiment towards Evolent Health is mostly neutral, so there could be opportunity for investors to get in on the ground floor. Evolent Health is a healthcare technology company that uses data and analytics to improve patient outcomes. The company has a strong focus on value-based care, which means that it is focused on providing quality care at a lower cost.
Evolent Health has a growing client base and is expanding its services to new markets. The company is well-positioned to continue its growth and offers investors an attractive opportunity to profit from the healthcare industry.
